Bausch Health Cos (NYSE:BHC) Trading Down 4.8% - Here's What Happened

Key Points

• Bausch Health Cos shares fell by 4.8% on Tuesday, trading as low as $6.83, with a total volume of approximately 2.6 million shares.
• Wall Street analysts have upgraded Bausch Health from a "hold" to a "buy" rating, with a consensus price target of $9.00.
• Director John Paulson acquired over 34 million shares of the company, significantly increasing his ownership stake, which reflects positive insider confidence in the stock.

Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) shares fell 4.8% during mid-day trading on Tuesday . The stock traded as low as $6.83 and last traded at $6.84. 2,593,839 shares traded hands during trading, a decline of 2% from the average session volume of 2,637,271 shares. The stock had previously closed at $7.18.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $9.00.

Bausch Health Cos Trading Down 2.3%

The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The company has a market cap of $2.49 billion, a P/E ratio of 25.89 and a beta of 0.48. The business has a 50-day moving average price of $6.90 and a two-hundred day moving average price of $6.08.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The firm had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of Bausch Health Cos stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the purchase, the director owned 70,755,869 shares of the company's stock, valued at $636,802,821. The trade was a 96.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 37,964,167 shares of company stock worth $333,757,793 over the last 90 days. 19.97% of the stock is owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

Institutional investors and hedge funds have recently modified their holdings of the stock. Cary Street Partners Financial LLC bought a new position in shares of Bausch Health Cos in the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd bought a new position in Bausch Health Cos in the 1st quarter valued at about $27,000. SBI Securities Co. Ltd. lifted its position in Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after acquiring an additional 3,001 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock worth $51,000 after acquiring an additional 3,106 shares during the period. Finally, Wealthquest Corp acquired a new position in shares of Bausch Health Cos in the first quarter valued at approximately $58,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.